DK1227810T3 - Behandling af cancer ved at foröge intracellulære malonyl-CoA-niveauer - Google Patents

Behandling af cancer ved at foröge intracellulære malonyl-CoA-niveauer

Info

Publication number
DK1227810T3
DK1227810T3 DK00978553T DK00978553T DK1227810T3 DK 1227810 T3 DK1227810 T3 DK 1227810T3 DK 00978553 T DK00978553 T DK 00978553T DK 00978553 T DK00978553 T DK 00978553T DK 1227810 T3 DK1227810 T3 DK 1227810T3
Authority
DK
Denmark
Prior art keywords
fatty acid
inhibition
cpt
malonyl coa
fas
Prior art date
Application number
DK00978553T
Other languages
Danish (da)
English (en)
Inventor
Craig A Townsend
Francis P Kuhajda
Ellen S Pizer
Original Assignee
Univ Johns Hopkins Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins Med filed Critical Univ Johns Hopkins Med
Application granted granted Critical
Publication of DK1227810T3 publication Critical patent/DK1227810T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Epoxy Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK00978553T 1999-11-12 2000-11-13 Behandling af cancer ved at foröge intracellulære malonyl-CoA-niveauer DK1227810T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16476599P 1999-11-12 1999-11-12
US16476899P 1999-11-12 1999-11-12

Publications (1)

Publication Number Publication Date
DK1227810T3 true DK1227810T3 (da) 2006-10-23

Family

ID=26860829

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00978553T DK1227810T3 (da) 1999-11-12 2000-11-13 Behandling af cancer ved at foröge intracellulære malonyl-CoA-niveauer

Country Status (12)

Country Link
US (1) US20020187534A1 (es)
EP (1) EP1227810B8 (es)
JP (1) JP2003513920A (es)
KR (4) KR20070106648A (es)
AT (1) ATE330598T1 (es)
AU (3) AU784495B2 (es)
CA (1) CA2391277A1 (es)
DE (1) DE60028996T2 (es)
DK (1) DK1227810T3 (es)
ES (1) ES2267587T3 (es)
PT (1) PT1227810E (es)
WO (1) WO2001034145A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1354196B1 (en) * 2000-11-27 2010-09-15 Minerva Biotechnologies Corporation Diagnostics, drug screening and treatment for cancer
WO2003037323A2 (en) * 2001-10-26 2003-05-08 MEDIGENE AG Gesellschaft für Molekularbiologische Kardiologie und Onkologie Inhibitors of the fatty acid oxidation for prophylaxis and treatment of diseases related to mitochondrial dysfunction
WO2003066043A1 (en) * 2002-02-08 2003-08-14 John Hopkins University School Of Medicine Stimulation of cpt-1 as a means to reduce weight
BRPI0312413A2 (pt) * 2002-07-01 2016-08-02 Fasgen Llc compostos, composições farmacêuticas contendo os mesmos, e método de utilização para os mesmos
US20070142456A1 (en) * 2002-10-31 2007-06-21 Fasgen, Llc Method for inhibiting cancer development by fatty acid synthase inhibitors
EP1594439A2 (en) 2003-02-13 2005-11-16 Albert Einstein College Of Medicine Of Yeshiva University REGULATION OF FOOD INTAKE AND GLUCOSE PRODUCTION BY MODULATION OF LONG-CHAIN FATTY ACYL-CoA LEVELS IN THE HYPOTHALAMUS
US8071645B2 (en) 2003-06-12 2011-12-06 The Regents Of The University Of Colorado Systems and methods for treating human inflammatory and proliferative diseases and wounds, with fatty acid metabolism inhibitors and/or glycolytic inhibitors
US7510710B2 (en) 2004-01-08 2009-03-31 The Regents Of The University Of Colorado Compositions of UCP inhibitors, Fas antibody, a fatty acid metabolism inhibitor and/or a glucose metabolism inhibitor
ITMI20040230A1 (it) * 2004-02-12 2004-05-12 Defiante Farmaceutica Lda Composti ad attivita' antitumorale
AU2006239896A1 (en) * 2005-04-28 2006-11-02 The Regents Of The University Of Colorado Therapeutic bifunctional compounds
EP1877047A2 (en) 2005-05-02 2008-01-16 The Regents of the University of Colorado Systems and methods for treating human inflammatory and proliferative diseases, with a combination of compounds, or a bifunctional compound,that provides fatty acid metabolism and glycolysis inhibition
WO2007117038A1 (ja) * 2006-04-07 2007-10-18 Japanese Foundation For Cancer Research 癌の予防・治療剤
WO2008106796A1 (en) * 2007-03-08 2008-09-12 University Health Network Induction of apoptosis and inhibition of cell proliferation through modulation of carnitine palmitoyltransferase 1c activity
WO2008109991A1 (en) 2007-03-09 2008-09-18 University Health Network Inhibitors of carnitine palmitoyltransferase and treating cancer
EP3048168A1 (en) * 2007-07-27 2016-07-27 Vesta Therapeutics, Inc. Methods of reducing intracellular fats from mammalian cells
US8680282B2 (en) * 2007-08-01 2014-03-25 University Health Network Cyclic inhibitors of carnitine palmitoyltransferase and treating cancer
US8394377B2 (en) 2008-02-21 2013-03-12 The Regents Of The University Of Colorado Methods for treating cancer using combination therapy
WO2010008554A2 (en) 2008-07-14 2010-01-21 The Regents Of The University Of Colorado Methods and products for treating proliferative diseases
JP5317919B2 (ja) * 2009-10-05 2013-10-16 花王株式会社 Ｇｉｐ上昇抑制剤の評価又は選択方法
AU2016219350A1 (en) 2015-02-10 2017-08-24 Minerva Biotechnologies Corporation Humanized anti-MUC1* antibodies
US20190300857A1 (en) * 2016-10-17 2019-10-03 Keio University Undifferentiated stem cell-removing agent, and method for removing undifferentiated stem cells
US20220244245A1 (en) * 2019-04-15 2022-08-04 INSERM (Institut National de la Santé et de la Recherche Médicale) A method of profiling the energetic metabolism of a population of cells
CN113604573A (zh) * 2021-09-14 2021-11-05 北京大学第三医院（北京大学第三临床医学院） 一种使用至少八种脂肪酸代谢关键酶基因检测方法以及试剂盒
CN113549702A (zh) * 2021-09-14 2021-10-26 北京大学第三医院（北京大学第三临床医学院） 一种人脂肪酸代谢关键酶基因检测方法以及试剂盒

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5759837A (en) * 1989-01-17 1998-06-02 John Hopkins University Chemotherapy for cancer by inhibiting the fatty acid biosynthetic pathway
MX9304501A (es) * 1992-07-24 1994-04-29 Univ Johns Hopkins Quimioterapia para cancer.
US5539132A (en) * 1994-01-24 1996-07-23 Johns Hopkins University Cerulenin compounds for fatty acid synthesis inhibition
US5981575A (en) * 1996-11-15 1999-11-09 Johns Hopkins University, The Inhibition of fatty acid synthase as a means to reduce adipocyte mass

Also Published As

Publication number Publication date
EP1227810B1 (en) 2006-06-21
EP1227810A1 (en) 2002-08-07
AU2009227836A1 (en) 2009-11-05
DE60028996D1 (de) 2006-08-03
DE60028996T2 (de) 2007-02-08
KR20070106648A (ko) 2007-11-02
EP1227810B8 (en) 2006-08-16
US20020187534A1 (en) 2002-12-12
KR20090031957A (ko) 2009-03-30
AU784495B2 (en) 2006-04-13
ATE330598T1 (de) 2006-07-15
KR20090130151A (ko) 2009-12-17
WO2001034145A1 (en) 2001-05-17
ES2267587T3 (es) 2007-03-16
CA2391277A1 (en) 2001-05-17
PT1227810E (pt) 2006-11-30
JP2003513920A (ja) 2003-04-15
AU2006203005A1 (en) 2006-08-10
KR20020060736A (ko) 2002-07-18
AU1600701A (en) 2001-06-06

Similar Documents

Publication Publication Date Title
DK1227810T3 (da) Behandling af cancer ved at foröge intracellulære malonyl-CoA-niveauer
Tseng et al. Inhibition of MDA‐MB‐231 breast cancer cell proliferation and tumor growth by apigenin through induction of G2/M arrest and histone H3 acetylation‐mediated p21WAF1/CIP1 expression
Anastasiou Tumour microenvironment factors shaping the cancer metabolism landscape
Vriend et al. The Keap1-Nrf2-antioxidant response element pathway: a review of its regulation by melatonin and the proteasome
Mullen et al. Progress in the development of fatty acid synthase inhibitors as anticancer targets
Yang et al. What has passed is prolog: new cellular and physiological roles of G6PD
Crack et al. Potential contribution of NF-κB in neuronal cell death in the glutathione peroxidase-1 knockout mouse in response to ischemia-reperfusion injury
Izzo et al. The bidirectional relationship between cancer epigenetics and metabolism
MA27609A1 (fr) Derives d'arylalkylcarbamates, leur preparation et leur application en therapeutique
Ding et al. Tyrosinase inhibitors isolated from the roots of Paeonia suffruticosa
ATE455550T1 (de) Verwendung eines extraktes aus angelica sinensis als wachstumsinhibitor von krebszellen in der tumortherapie
Li et al. LFG-500 inhibits the invasion of cancer cells via down-regulation of PI3K/AKT/NF-κB signaling pathway
ATE435858T1 (de) Prodrugs von als erk-proteinkinase-inhibitoren wirkenden pyrrolylpyrimidinen
DK1603941T3 (da) Inhibitorer af ekstracellulær Hsp90
ATE487475T1 (de) Heterocyclische verbindungen als nützliche malonyl-coa decarboxylase-hemmer
Coronel-Hernández et al. Aberrant metabolism as inductor of epigenetic changes in breast cancer: therapeutic opportunities
Lange et al. Hydropersulfides are endogenous antioxidants that inhibit ferroptosis
Wang et al. Apigenin inhibits human SW620 cell growth by targeting polyamine catabolism
NO20020829L (no) Ny anvendelse av docetaxel for behandling av hepatoma
EP2633856A3 (en) ATP citrate lyase inhibitors for treating cancer
Yao et al. Targeting RAS‐converting enzyme 1 overcomes senescence and improves progeria‐like phenotypes of ZMPSTE24 deficiency
EA200500958A1 (ru) Дейтерированные производные катехоламина, а также лекарственные средства, содержащие эти соединения
Kashyap et al. Efficacy of selinexor is dependent on IκB-α expression and NF-kb deactivation in multiple myeloma cells
DK1565176T3 (da) Middel med ödelæggende virkning på maligne rumorer samt fremgangsmåde til fremstilling heraf
Flores-López et al. Parthenolide and DMAPT induce cell death in chronic myeloid leukemia cells via generation of reactive oxygen species